“For example, the most well-known of these immunotherapies only benefits 20 to 30% of patients.” When they delivered the Cas13 package into tumor microenvironments in mice, they found that it silenced ...
Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback